ToxStrategies Acquires Suttons Creek
August 13, 2024
ToxStrategies, a Renovus Capital Partners portfolio company, has acquired Suttons Creek to expand its combination-product development and regulatory consulting capabilities. Brookside Capital Partners provided financing to support the add-on acquisition; Suttons Creek will operate as a division of ToxStrategies and its founder Steven Badelt will continue to lead the business. Terms were not disclosed.
- Targets
- Suttons Creek
- Platforms
- ToxStrategies
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Renovus-Backed BlueRidge Life Sciences Formed by Uniting Suttons Creek, Modality Solutions, CLINTREX and ToxStrategies
August 25, 2025
Healthcare Services
Four life-sciences consulting firms — Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies — have been unified under the new brand BlueRidge Life Sciences to create an integrated life-sciences services platform. The move, backed by private equity sponsor Renovus Capital Partners, consolidates toxicology, regulatory science, engineering, clinical research and related capabilities to offer end-to-end scientific and regulatory support to pharmaceutical, biotech, medical device and consumer-product clients.
-
ToxStrategies Acquires Clintrex Research Corporation
June 25, 2024
Healthcare Services
ToxStrategies, a Renovus Capital Partners–backed scientific consulting firm based in Katy, Texas, has acquired Clintrex Research Corporation, a Sarasota-based clinical and regulatory development services provider focused on neurodegenerative and CNS therapies. The deal (terms undisclosed) expands ToxStrategies' clinical, regulatory, biostatistics and drug‑development capabilities and is intended to broaden its end‑market reach in the life sciences sector.
-
ToxStrategies (Renovus-backed) Acquires Modality Solutions
August 8, 2023
Healthcare Services
ToxStrategies, a Renovus Capital Partners-backed life sciences consulting platform, has acquired Modality Solutions, a Houston-based firm specializing in biopharmaceutical cold-chain optimization and shipping validation testing. The add-on expands ToxStrategies' cold-chain, package engineering, and regulatory testing capabilities and will operate as a division of ToxStrategies with Modality's founders continuing to lead the business.
-
Renovus Capital Partners Majority Investment in ToxStrategies
January 24, 2023
Healthcare Services
Renovus Capital Partners made a majority investment in ToxStrategies, a multidisciplinary scientific consulting firm specializing in toxicology, epidemiology, exposure sciences and regulatory compliance. Five Points Capital provided debt and equity co-investment to support the transaction; terms were not disclosed and the deal was described as a recapitalization to support growth and expand services, staff and geographic reach.
-
Charles River Associates Acquires bioStrategies Group
November 29, 2022
Consulting
Charles River Associates (CRA) acquired substantially all assets of bioStrategies Group, a Chicago-based life sciences commercial strategy consulting firm, and retained 17 employees. The deal expands CRA's Life Sciences Practice capabilities and geographic presence by adding experienced consultants including Mike Kaestle and Chris Schneider.
-
Bain & Company Acquires Sutton Place Strategies
December 21, 2020
Data & Analytics
Bain & Company has acquired Sutton Place Strategies (SPS), a deal origination tool and transaction database used by private equity firms, corporate M&A teams, and deal advisors. The acquisition adds SPS's proprietary transaction data and analytics to Bain's suite of data offerings to enhance deal sourcing, pipeline analytics, and M&A advisory capabilities.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.